Kisspeptin

In simple words

Kisspeptin is a natural "gatekeeper" peptide that switches on the brain's reproductive hormone axis. It is being studied for triggering ovulation in IVF, for menstrual cycle disorders, and for low sexual desire.

What this molecule is

KP-10: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂ (10 aa). KP-54: 54 aa. MVT-602: structurally stabilized analog. KISS1 gene.

Why it is studied

Gatekeeper of the reproductive axis. 5 RCTs in JAMA Netw Open and J Clin Invest (2020-2025). Intranasal KP-54 stimulates LH/FSH in healthy individuals and in hypothalamic amenorrhea. MVT-602 as an ovulation trigger in IVF (phase 3). RCTs: improved sexual behavior in men and women with HSDD.

How it works

KISS1R (GPR54) agonist on hypothalamic neurons → ↑GnRH neurons → ↑GnRH pulsatility → ↑LH/FSH. A key integrator of metabolic status signals (leptin, insulin) with reproductive function. Central libido mechanism via the limbic system.

Doses used in studies

Clinical studies used KP-10 IV at ~0.1–1 nmol/kg. Intranasal KP-54: research protocols. MVT-602 SC: phase 3. Only under the supervision of a reproductive specialist/endocrinologist.

Combined with in studies

• GnRH stimulation testing
• Hormone tests — LH/FSH/testosterone/estradiol
• GnRH agonists/antagonists — NOT compatible without supervision

Level of evidence

Level A Human clinical trials. There are randomized controlled trials (RCTs), or the compound has been approved by a regulatory agency. The most reliable level. 5 RCTs in JAMA and J Clin Invest. MVT-602 in Phase 3.

Important to know

⚠️ Used only in research and diagnostic protocols. Not suitable for self-use. Consultation with a reproductive specialist is mandatory.

Studies in PubMed

1. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. (EBioMedicine, 2025)
2. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. (JAMA Netw Open, 2023)
3. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. (JAMA Netw Open, 2022)
4. Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals. (Fertil Steril, 2024)
5. Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. (J Clin Invest, 2020)